Abstracts tagged "Anti-TNF Drugs"

Abstract Number: LB06 • ACR Convergence 2025
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Frank Behrens¹, Patrizia Sternad², Klaus Krueger³, Christine App⁴, Stephanie Lefevre⁴ and Christiane Schiedel⁴, ¹Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ²Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ³Rheumatologisches Praxiszentrum, München, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Psoriatic arthritis (PsA) patients with prior failure or intolerance to TNFα inhibitors (TNFi) represent a clinically challenging population with limited therapeutic options. The AgAIN…
Abstract Number: 2359 • ACR Convergence 2025
Combination Of TNF Inhibitors And NSAIDs Versus TNF Inhibitors Alone On The Progression Of Structural Damage In The Spine And Hip: a Retrospective Study In 262 Patients With Radiographic Axial Spondyloarthritis
MARIA KONSTA¹, Michael Nurmohamed², Alexios Iliopoulos³, Petros Sfikakis⁴, Ingrid Visman⁵, Grigorios Sakellariou⁶ and Irene E. van der Horst-Bruinsma⁷, ¹Sismanoglion Hospital, Athens, Greece, Marousi, Attiki, Greece, ²Amsterdam Rheumatology and Immunology Center, Reade; Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³⁴¹⁷ Army Share Fund Hospital (NIMTS), Department of Rheumatology, Athens, Greece, ZOGRAFOU, Greece, ⁴NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁵Reade Amsterdam, Amsterdam, Noord-Holland, Netherlands, ⁶⁴²⁴ General Military Hospital, Thessaloniki, Greece, ⁷Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: The inhibitory effect of TNF inhibitor (TNFi) treatment on spinal radiographic progression in patients with radiographic Axial Spondyloarthritis (r-axSpA), remains controversial. However, current evidence…
Abstract Number: 1095 • ACR Convergence 2025
Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
dellal azeddine¹, Jean-Guillaume Letarouilly², Jacques Morel³, René-Marc Flipo⁴, Valerie Devauchelle⁵, richette pascal⁶, Philippe Dieude⁷, Hubert Marotte⁸, FELTEN Renaud⁹, LATOURTE Augustin¹⁰, CHEVET Baptiste¹¹, HILLIQUIN Pascal¹², SORDET Christelle⁹, DERNIS mmanuelle¹³, WENDLING Daniel¹⁴, Arsène Mekinian¹⁵, Nathalie BALLANDRAUD¹⁶, Christophe Richez¹⁷, TOURNADRE Anne¹⁸, salmon Jean -Hugues¹⁹, SAILLOT Carine²⁰, kedra joanna²¹, nahon stephane²², LE GOFF Benoit²³, Bruno Fautrel²⁴, Francis BERENBAUM²⁵, David SAADOUN²⁶, PHAM Thao¹⁶ and SELLAM JEREMIE²⁷, ¹GHI LE RAINCY MONTFERMEIL, Montfermeil, France, ²Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, LILLE, Nord-Pas-de-Calais, France, ³CHU and University of Montpellier, Montpellier, France, ⁴Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁵UBO, Brest, France, ⁶Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, ⁷Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ⁸INSERM ¹⁰⁵⁹/University of Saint-Etienne, Saint-Etienne, France, ⁹Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ¹⁰Rheumatology Department, Lariboisiere Hospital, Paris, France, ¹¹CHU BREST, brest, Bretagne, France, ¹²CH SUD FRANCILIEN, PARIS, France, ¹³chu caen, CAEN, Haute-Normandie, France, ¹⁴CHU de Besançon, Besançon, Franche-Comte, France, ¹⁵Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁶CHU MARSEILLE, marseille, Provence-Alpes-Cote d'Azur, France, ¹⁷Bordeaux University Hospital, Bordeaux, France, ¹⁸CHU CLERMONT, CLERMONT, Lorraine, France, ¹⁹CHU REIMS, REIMS, Champagne-Ardenne, France, ²⁰CHU ORLEANS, ORLEANS, Pays de la Loire, France, ²¹Pitié-Salpêtrière Hospital, Rheumatology Department, APHP, Sorbonne University,, Paris, France, ²²GHI LE RAINCY MONTFERMEIL, Montfermeil, Ile-de-France, France, ²³CHU Nantes, Nantes, France, ²⁴Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ²⁵Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ²⁶CHU LA PITIE SALPETRIERE, PARIS, Ile-de-France, France, ²⁷Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France
Background/Purpose: The use of TNFα antagonist is not recommended if the patient have a suspicion or demyelinating diseases (DD) confirmed [1]. There are a few…
Abstract Number: 0052 • ACR Convergence 2025
Profiling of MT-3534, a Humanized Monoclonal Antibody Targeting Peptidylarginine Deiminase 4, as a Candidate Drug for the Treatment of RA
Hisae Niki¹, Akitoshi Nishizawa², Yuuichi Ono¹, Makoto Yamazaki¹, Satoshi Takanashi³, Keiko Yoshimoto⁴, Mitsuhiro Akiyama³, Tsutomu Takeuchi⁵ and Yuko Kaneko⁴, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ²Mitsubishi Tanabe Pharma Corporation, Fujisawa, Kanagawa, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁵Saitama Medical University and Keio University, Tokyo, Japan
Background/Purpose: Although the management of rheumatoid arthritis (RA) has been remarkably improved, there are still patients who have not responded to existing targeted drugs that…
Abstract Number: 2338 • ACR Convergence 2025
Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
Aashish Agrawal and Balakrishnan Canchi, Hinduja Hospital, Mumbai, Maharashtra, India
Background/Purpose: The use of combination biologic and targeted synthetic DMARDs remains controversial due to safety concerns, yet may offer benefit in refractory inflammatory arthritis. This…
Abstract Number: 0996 • ACR Convergence 2025
Breaking Inflammatory Pathways: ELN28, a Novel Dual TNFα/JAK Inhibitor Drug Conjugate for Chronic Inflammation
Obinna Ubah, Euan Murray, Stella Priyanka, Julia Martinez Fraile, Andrew Porter, Robert Boyd and Caroline Barelle, Elasmogen Limited, Aberdeen, United Kingdom
Background/Purpose: Despite advances in therapies for chronic autoimmune diseases such as rheumatoid arthritis (RA), significant unmet needs persist, including therapeutic ceiling effects, adverse events, and…
Abstract Number: 0035 • ACR Convergence 2025
Clinical and Transcriptomic Heterogeneity in Patients With RA: A Multi-Centric International Study of Anti-TNF Response
Maryna Borshchivska¹, Thibault Helleputte¹, Laurent Meric de Bellefon², Silvana di Romana³, Elsa Vieira-Sousa⁴, Vasco Romão⁴, João Eurico Fonseca⁵, Alla Ishchenko⁶, Patrick Verschueren⁶, Ruth Wittoek⁷, Peggy jacques⁷, Dirk Elewaut⁸, Bernard Lauwerys⁹ and Patrick Durez¹⁰, ¹DNAlytics, Louvain-la-Neuve, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Belgium, ³Department of Rheumatology, Saint Pierre University Hospital, Brussels, Belgium, ⁴Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Portugal, ⁵Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Lisboa, Portugal, ⁶Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium, ⁷VIB Center for Inflammation Research, Ghent University and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁹Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ¹⁰Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can lead to joint damage and disability. Although methotrexate is the standard first-line treatment, about…
Abstract Number: 2284 • ACR Convergence 2025
Cardiovascular Outcomes in Diabetic Rheumatoid Arthritis Patients: TNF-α Inhibitors versus IL-6 Inhibitors
Sila Mateo Faxas¹, Godbless Ajenaghughrure¹, Gurjot Singh², Kim Nguyen², Nirys Mateo Faxas³, Nicole Tejeda⁴, Kimberly Ramirez Bonetti⁵ and Erick Perez Mejias⁴, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Trihealth Good Samaritan Hospital, Cincinnati, ³Independent Author, Santo Domingo, Dominican Republic, ⁴Independent Author, Cincinnati, ⁵Independent Author, cincinnati, OH
Background/Purpose: Patients with rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) face increased cardiovascular risk. Different biologic disease-modifying antirheumatic drugs (bDMARDs) may have varying…
Abstract Number: 0570 • ACR Convergence 2025
Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
Gilad Halpert¹, Eri Govrin¹, Omer Gendelman¹, Abdulla Watad², Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: A substantial number of patients with rheumatic inflammatory/autoimmune diseases, do not achieve adequate symptom control with current standard-of-care therapies, including biologics. The endocannabinoid system…
Abstract Number: 0021 • ACR Convergence 2025
DoCTIS: A Single Cell RNA-Seq Atlas of Drug Response To Targeted Therapies
Antonio Julià¹, Yolanda Guillén², Paloma Vela Casasempere³, Antonio Fernández Nebro⁴, Carlos Marras⁵, Santos Castañeda⁶, Jaime Calvo Alén⁷, Jesús Tornero Molina⁸, Juan Cañete⁹, Eugeni Domènech¹⁰, Javier Gisbert¹¹, Jose M. Carrascosa¹², Eduardo Fonseca¹³, Luis Bujanda Fernández De pierola¹⁴, Valle García Sánchez¹⁵, Britta Siegmund¹⁶, Giampiero Girolomoni¹⁷, Holger Heyn¹⁸, Laura Jiménez Gracia¹⁸, Pere Santamaria¹⁹, Edgar Angelats²⁰, Richard Myers²¹, Sergio H. Martínez Mateu², Juan Ángel Patiño Galindo², Ernest Choy²² and Sara Marsal¹, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²IMIDomics, Barcelona, Spain, ³Hospital General Universitario de Alicante, Rheumatology, Alicante, Spain, ⁴Hospital Regional Universitario Carlos Haya, Rheumatology, Málaga, Spain, ⁵Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Spain, ⁶Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁷Hospital Universitario de Araba, Rheumatology, Vitoria, Spain, ⁸Hospital Universitario de Guadalajara, Rheumatology, Guadalajara, Spain, ⁹Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ¹⁰Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain, ¹¹Hospital Universitario La Princesa, Rheumatology, Madrid, Spain, ¹²Hospital Universitari Germans Trias i Pujol, Dermatology, Badalona, Spain, ¹³Complejo Hospitalario Universitario de A Coruña, Dermatology, A Coruña, Spain, ¹⁴Hospital Universitario de Donostia, Gastroenterology, San Sebastián, Spain, ¹⁵Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain, ¹⁶Charité-Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany, ¹⁷University of Verona, Dermatology, Verona, Spain, ¹⁸Centre for Genomic Regulation (CNAG-CRG), Barcelona, Spain, ¹⁹Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelonoa, Spain, ²⁰Hospital Clínic-IDIBAPS, Barcelona, Spain, ²¹HudsonAlpha Institute for Biotechnology, Huntsville, AL, ²²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Targeted therapies have revolutionized the management of immune-mediated inflammatory diseases (IMIDs), however, there is a substantial number of patients who respond poorly to a…
Abstract Number: 2274 • ACR Convergence 2025
Importance Of Fc Region On Therapeutic Survival In Rheumatoid Arthritis Patients With Anti-TNF Therapy
ELENA GRAU GARCIA¹, Iago Alcántara Álvarez², Jose Ivorra Cortes³, Pablo Muñoz Martinez⁴, Laura Mas Sanchez⁵, Alba Maria Torrat Noves⁶, Daniel Ramos Castro⁷, Belen Villanueva Manes⁸, Miguel Simeo Vinaixa⁴, Andres Perez Hurtado⁹ and José Andrés Román Ivorra¹⁰, ¹HUP La Fe, Valencia, Comunidad Valenciana, Spain, ²Hospital Universitari i Politénic La Fe, València, Spain, ³Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Valencia, Spain, ⁵Hospital Universitari i Politecnic La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁸Hospital La Fe, València, Spain, ⁹Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ¹⁰Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: In patients affected by rheumatoid arthritis (RA), it has been studied a relation between high rheumatoid factor (RF) and a favorable response to anti-TNF…
Abstract Number: 0568 • ACR Convergence 2025
Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial
caroline Damen¹, Philippe Carron², Ann-Sophie De Craemer³, Filip Van den Bosch³ and Dirk Elewaut⁴, ¹Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, ²Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ³Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁴VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium
Background/Purpose: Peripheral spondyloarthritis (pSpA) is a neglected clinical entity with few therapeutic or clinical management trials available to date. In the CRESPA-trial (1) very early…
Abstract Number: 2271 • ACR Convergence 2025
Assessing the Real-World Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic DMARDs on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
Daniel Aletaha¹, Dr. Carmen Bremer², Jack Milligan³, Zichun Cao⁴, Rachael Meadows³ and Xenofon Baraliakos⁵, ¹Medical University Vienna, Wien, Austria, ²Sandoz International GmbH, Holzkirchen, Germany, ³Adelphi Real World, Macclesfield, United Kingdom, ⁴Sandoz Incorporated, Princeton, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Early use of targeted therapy (TT), such as anti-tumor necrosis factor (anti-TNF) biologics, show improved outcomes for RA1, but costs often limit access. Biosimilars,…
Abstract Number: 0560 • ACR Convergence 2025
Single Cell Sequencing Analysis of Tumour Necrosis Factor Inhibitor Drug Response Reveals Enrichment of Pro-inflammatory Pathway in Non-responders and Amino Acid Metabolic Pathways in Responders
Ayantika Talukdar¹, Phuong Nguyen², Neke Ibeke³, Rohan Machhar¹, Mansi Aparnathi¹, Archita Srinath², Akihiro Nakamura⁴, Robert Inman³, Igor Jurisica⁵, Proton Rahman⁶, Nigil Haroon⁷ and Sareh Keshavarazi¹, ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Queen's University, Kingston, ON, Canada, ⁵University Health Network, Toronto, Canada, ⁶Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁷Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Ankylosing Spondylitis (AS) is a type of chronic inflammatory arthritis affecting the spine and peripheral joints. Although tumor necrosis factor inhibitors (TNFi) substantially improve…
Abstract Number: 2268 • ACR Convergence 2025
Differential Impact of Certolizumab Pegol, Etanercept, and Adalimumab on Rheumatoid Factor Reduction and Seroconversion in Rheumatoid Arthritis: A Propensity Score–Matched Study
Clementina López Medina¹, Rafaela Ortega-Castro², Francisco Jose Cepas³, Montserrat Robustillo-Villarino⁴, Andres Zuniga-Vera⁴, Ana Martinez-Feito⁵, Ester Costa-Moya⁶, Delia Taverner-Torrent⁶, Luis Sainz Comas⁷, Cesar Diaz-Torne⁷, Virginia Ruiz-Esquide⁸, Cynthia Rojas⁹, Lourdes Martin-de la Sierra Lopez¹⁰, Laura Jimenez-Rodriguez¹⁰, David Velasco-Sanchez¹⁰, Regina Fará Garcia¹¹, Antonio Juan-Mas¹², Marina soledad Moreno Garcia¹³, Ana Valeria Acosta Alfaro¹⁴, Santiago Muñoz¹⁵, Maria Martín López¹⁶, Raquel Zas¹⁷, FRANCISCO JAVIER GODOY NAVARRETE¹⁸, Isabel Anon Onate¹⁹, Fernando Ortiz-Márquez²⁰, Natalia Mena Vázquez²¹, Paula Estrada-Alarcón²², Jerusalén Calvo²³, Alejandro Escudero Contreras²³ and Chamaida Plasencia-Rodríguez²⁴, ¹Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³University of Cordoba, Cordoba, Spain, ⁴Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, ⁵Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁶Hospital Sant Joan Reus, Reus, Spain, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁹Hospital Clinic, Barcelona, Spain, ¹⁰Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹¹Hospital Son Llàtzer, Palma, Spain, ¹²Son Llazter University Hospital, Madrid, Spain, ¹³Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁴Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁶Hospital ¹² de Octubre, Madrid, Spain, ¹⁷Hospital Universitario Doce de Octubre, Madrid, Spain, ¹⁸Jaen University Hospital, Spain, Jaen, Spain, ¹⁹Hospital Universitario de Jaén, Jaén, Spain, ²⁰Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, ²¹Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ²²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ²⁴Hospital Universitario La Paz, MADRID, Spain
Background/Purpose: Rheumatoid factor (RF) is an antibody that contributes to the development of rheumatoid arthritis (RA) and is associated with greater disease severity. Seroconversion of…

1
2
3
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].